|
| ID |
DDInter174 |
| Drug Type |
small molecule |
| Molecular Formula |
C15H14N2O4S |
| Molecular Weight |
318.353
|
| Description |
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
|
| ATC Classification |
L01XX49
|
| IUPAC Name |
(2E)-N-Hydroxy-3-[3-(Phenylsulfamoyl)Phenyl]Prop-2-Enamide |
| InChI |
Inchi=1S/C15H14N2O4S/C18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/H1-11,17,19H,(H,16,18)/B10-9+ |
| InChI Key |
NCNRHFGMJRPRSK-MDZDMXLPSA-N |
| Canonical SMILES |
ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1 |
| Useful Links |
DrugBank
ChEMBL
|